1. Home
  2. KFFB vs RNTX Comparison

KFFB vs RNTX Comparison

Compare KFFB & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kentucky First Federal Bancorp

KFFB

Kentucky First Federal Bancorp

HOLD

Current Price

$4.51

Market Cap

39.2M

Sector

Finance

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

N/A

Current Price

$1.60

Market Cap

42.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KFFB
RNTX
Founded
2005
2001
Country
United States
United States
Employees
N/A
10
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.2M
42.9M
IPO Year
2004
N/A

Fundamental Metrics

Financial Performance
Metric
KFFB
RNTX
Price
$4.51
$1.60
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
1.5K
118.2K
Earning Date
05-11-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
109.52
N/A
EPS
0.08
N/A
Revenue
$15,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$56.38
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.96
$1.02
52 Week High
$4.98
$2.22

Technical Indicators

Market Signals
Indicator
KFFB
RNTX
Relative Strength Index (RSI) 54.36 68.31
Support Level $4.48 $1.08
Resistance Level $4.89 $2.18
Average True Range (ATR) 0.15 0.18
MACD 0.02 0.03
Stochastic Oscillator 71.95 89.83

Price Performance

Historical Comparison
KFFB
RNTX

About KFFB Kentucky First Federal Bancorp

Kentucky First Federal Bancorp is a holding company. The company, through its subsidiaries, is engaged mainly in the business of accepting deposits from the general public and using such funds to originate loans secured by first mortgages on owner-occupied, residential real estate and other loans secured by real estate. Its primary products and services include Residential mortgage loans, Multi-family loans, Construction loans, and types of deposits etc. The company mainly operates in Perry, Franklin, Boyle, and Garrard and surrounding counties in Kentucky, USA.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: